Accueil   Agenda - News   Toutes les news CEA-Leti breakthrough opens path to new vaccine for HIV using lipid-nanoparticle-delivery technology

CEA-Leti breakthrough opens path to new vaccine for HIV using lipid-nanoparticle-delivery technology

 

GRENOBLE, France – Feb. 27, 2019 – Leti, a research institute of CEA Tech, in collaboration with CEA's Fundamental Research Division, has developed a new vaccine approach for HIV based on engineered lipid nanoparticles that deliver p24 - a viral protein that is key to an HIV vaccine- and optimize the CpG adjuvant's effect.

 

Until now, p24-based vaccines have shown limited effectiveness because of an insufficient immune response to this antigen in HIV patients. Based on its Lipidots® delivery platform, CEA-Leti's new approach improves immunogenicity against the p24 HIV protein by loading it and an immunostimulant agent onto nanostructured lipid carriers (NLCs). This may be a first step for a new HIV vaccine that also would include additional components of the virus.

 

Lire le communiqué de presse complet

En poursuivant votre navigation sur ce site, vous acceptez l'utilisation de cookies pour vous proposer des services et offres adaptés à vos centres d'intérêt. En savoir plus... Fermer